AD is characterized by the progressive loss of cognitive functions and memory, but can also be accompanied by neurobehavioral manifestations. Mild cognitive impairment (MCI) is thought to be the intermediate stage between expected cognitive decline of normal aging and the more pronounced decline seen in dementia. According to the 2011 updates guidelines for AD, the symptomatic predementia phase of AD is now referred to as MCI due to AD. There have been several studies and reviews performed on evaluating the effectiveness of melatonin in AD patients with sleep disorders and in patients with mild cognitive impairment. A review of melatonin physiological activities and evidence-based therapeutic interventions in patients with mild cognitive impairment and Alzheimer disease.
The goal of peer-review is to assess the quality of articles submitted for publication in a Scholarly Open Access Journals. Peer-reviewed articles provide a trusted form of scientific communication. The peer review process is highly appreciated by researchers globally.
Last date updated on July, 2014